Elias Jabbour, MD, discusses findings from the PhALLCON trial relevant to treatment decisions for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA; Jonathan Abbas, MD; Elias Jabbour, MD; James K. McCloskey, MD; Vivian Tambe Ebot-Tar, PharmD, MBA.
Dr Jabbour discussed recent phase 3 PhALLCON trial (NCT03589326) data, supporting more potent third-generation tyrosine kinase inhibitor (TKI) ponatinib’s move to the frontline for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Adding ponatinib up front doubled minimal residual disease negativity complete response rates vs standard second-generation TKIs, meeting the primary end point. More patients avoided transplant, with improved event-free survival. Manageable cardiovascular risk was shown with dose adjustment. Dr McCloskey addressed challenges in Ph+ ALL and said selecting optimal TKI therapy is still based on patient factors, but ponatinib’s early activity and favorable safety support its use earlier in therapy to improve outcomes.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More